Gilead Sciences, Inc. (GILD) Holdings Raised by Banced Corp
Banced Corp raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,691 shares of the biopharmaceutical company’s stock after purchasing an additional 899 shares during the quarter. Gilead Sciences accounts for 1.3% of Banced Corp’s portfolio, making the stock its 19th largest position. Banced Corp’s holdings in Gilead Sciences were worth $686,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of GILD. Keel Point LLC lifted its holdings in Gilead Sciences by 0.4% during the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 11 shares during the last quarter. West Oak Capital LLC lifted its holdings in Gilead Sciences by 0.7% during the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares during the last quarter. Westover Capital Advisors LLC lifted its holdings in Gilead Sciences by 0.8% during the 1st quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 46 shares during the last quarter. Abner Herrman & Brock LLC lifted its holdings in Gilead Sciences by 0.5% during the 1st quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 50 shares during the last quarter. Finally, ARS Investment Partners LLC lifted its holdings in Gilead Sciences by 0.9% during the 1st quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 73.97% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ:GILD) traded up 0.79% during mid-day trading on Friday, reaching $83.27. The company had a trading volume of 5,654,657 shares. The stock has a market cap of $108.74 billion, a PE ratio of 9.04 and a beta of 1.19. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The firm’s 50-day moving average price is $77.54 and its 200-day moving average price is $70.38.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s revenue was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.08 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post $8.78 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.50%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
A number of research firms have commented on GILD. BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a report on Thursday, August 31st. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 target price on the stock. in a report on Monday, August 28th. Cowen and Company reaffirmed an “outperform” rating and set a $90.00 target price on shares of Gilead Sciences in a report on Wednesday, July 5th. Finally, Wells Fargo & Company increased their target price on Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a report on Wednesday, September 6th. Eleven analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $84.29.
In other news, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $83.05, for a total transaction of $2,076,250.00. Following the completion of the transaction, the executive vice president now directly owns 101,488 shares in the company, valued at approximately $8,428,578.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The disclosure for this sale can be found here. In the last quarter, insiders have sold 466,819 shares of company stock valued at $36,740,240. Corporate insiders own 1.30% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/gilead-sciences-inc-gild-holdings-raised-by-banced-corp/1583262.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.